Our results showed that ZGGS15 can competitively inhibit the binding of LAG-3 with MHC-II and the binding of TIGIT with CD155, supporting the potential clinical applications of ZGGS15 in cancer patients with high FGL1 expression (e.g., hepatocellular carcinoma)56. Here, TIGIT is linked to hepatocellular carcinoma.